Medicare’s GLP-1 spending is skyrocketing, even without weight loss coverage: KFF
Gross Medicare spending on the pricey drugs rose from $57 million in 2018 to $5.7 billion in 2022, according to a new analysis from the health policy group.
Gross Medicare spending on the pricey drugs rose from $57 million in 2018 to $5.7 billion in 2022, according to a new analysis from the health policy group.